TY - JOUR
T1 - Advanced Nanomedicine
T2 - Redefining Therapeutic Paradigms for Inflammatory Bowel Disease
AU - Zhang, Yinfeng
AU - Wang, Tingting
AU - Sun, Meng
AU - Song, Yueyue
AU - Huang, Xinyuan
AU - Zhang, Shutian
AU - Yang, Jun
AU - Zhang, Jinfeng
N1 - Publisher Copyright:
© 2023 Wiley-VCH GmbH.
PY - 2023/7/27
Y1 - 2023/7/27
N2 - Inflammatory bowel disease (IBD), a chronic and recurrent gastrointestinal inflammatory disorder with a variety of painful clinical manifestations and an increased risk of cancerization or death, has become an emerging challenge to global healthcare due to its rapidly increasing incidence. At present, there is no efficient cure against IBD because of the elusive etiology and pathogenesis of IBD. Therefore, the development of alternative therapeutic strategies with positive clinical efficacy and reduced side effects is urgently needed. In recent years, the great prosperity of nanomedicine promoted by a variety of advanced nanomaterials is redefining more attractive and promising therapeutic strategies for IBD owing to their advantages in the physiological stability, bioavailability, and targeting of inflammatory sites. In this review, firstly the basic characteristics of healthy and inflammatory intestinal microenvironments are presented. Then, different administration routes and targeting strategies of nanotherapeutics for IBD treatment are reviewed. Subsequently, a specific focus is placed on the introduction of nanotherapeutic treatments based on different IBD pathogenesis. Finally, some future challenges and perspectives of the currently developed nanomedicines for IBD treatment are provided. It is believed that the above topics will attract researchers from various fields including medicine, biological sciences, materials, chemistry and pharmaceutics.
AB - Inflammatory bowel disease (IBD), a chronic and recurrent gastrointestinal inflammatory disorder with a variety of painful clinical manifestations and an increased risk of cancerization or death, has become an emerging challenge to global healthcare due to its rapidly increasing incidence. At present, there is no efficient cure against IBD because of the elusive etiology and pathogenesis of IBD. Therefore, the development of alternative therapeutic strategies with positive clinical efficacy and reduced side effects is urgently needed. In recent years, the great prosperity of nanomedicine promoted by a variety of advanced nanomaterials is redefining more attractive and promising therapeutic strategies for IBD owing to their advantages in the physiological stability, bioavailability, and targeting of inflammatory sites. In this review, firstly the basic characteristics of healthy and inflammatory intestinal microenvironments are presented. Then, different administration routes and targeting strategies of nanotherapeutics for IBD treatment are reviewed. Subsequently, a specific focus is placed on the introduction of nanotherapeutic treatments based on different IBD pathogenesis. Finally, some future challenges and perspectives of the currently developed nanomedicines for IBD treatment are provided. It is believed that the above topics will attract researchers from various fields including medicine, biological sciences, materials, chemistry and pharmaceutics.
KW - gut microbiota
KW - inflammatory bowel disease (IBD)
KW - macrophage polarization
KW - nanotherapeutics
KW - reactive oxygen species (ROS)
UR - http://www.scopus.com/inward/record.url?scp=85152045427&partnerID=8YFLogxK
U2 - 10.1002/adhm.202300069
DO - 10.1002/adhm.202300069
M3 - Review article
C2 - 36929291
AN - SCOPUS:85152045427
SN - 2192-2640
VL - 12
JO - Advanced healthcare materials
JF - Advanced healthcare materials
IS - 19
M1 - 2300069
ER -